CRANBURY, N.J., Jan. 4 /PRNewswire/ -- Linguagen Corp. (http://www.linguagen.com), a leader in the development of new compounds to improve the taste and quality of pharmaceutical, food and beverage products, announces the appointment of Susan Welsh, MD, MBA, to the position of President. Dr. Welsh will be responsible for the Company’s pharmaceutical product development efforts as well as the Company’s business development strategy and execution. The appointment highlights Linguagen’s progress advancing its research programs into development and commercial opportunities.
“Dr. Welsh has unusually broad experience ranging from strategic portfolio creation through managing development and commercialization of novel pharmaceutical products,” said Ray Salemme, Ph.D., CEO of Linguagen Corp. “We are excited that Dr. Welsh is joining our management team at this crucial stage of Linguagen’s evolution and look forward to her contributions as we implement our strategy, advance our products, and foster new relationships with business partners.”
Prior to joining Linguagen, Dr. Welsh was Group Vice President, Global Project Management at Schering-Plough, where she was responsible for all aspects of global project management including the R&D licensing function. She also served as a member of Schering-Plough’s Pharmaceutical Leadership Board. Prior to Schering Plough, Dr. Welsh held senior business and pharmaceutical development positions at Johnson & Johnson, Pharmacia, Syntex, Alza, and SmithKline Beecham. During her career, Dr. Welsh has spent nearly 20 years in the management of global pharmaceutical product development and commercialization. Prior to joining industry, Dr. Welsh served as a commissioned officer in the Royal Air Force, where she ran acute and ambulatory care units throughout the world.
Dr. Welsh holds a BSc and an MBChB (Bachelor of Medicine and Bachelor of Surgery) from the University of Leeds, United Kingdom, an MBA from the University of California at Berkeley, and a Master’s of Information Management from Washington University. She is on the faculty at Stanford School of Medicine, and is a Fellow of the Faculty of Pharmaceutical Medicine and Royal Colleges of Physicians, U.K. She also serves as a member of the Board of Advisors of the New Jersey Medical School and the National Council, School of Engineering and Applied Science at Washington University in St. Louis.
About Linguagen
Linguagen Corp. (http://www.linguagen.com) is a biotechnology firm that identifies and develops compounds to improve the taste of pharmaceutical, food and beverage products. Linguagen’s pharmaceutical program focuses on a unique biochemical approach to bitterness suppression of medicines that many patients find unpalatable. Reducing the bitter taste of medicines will expand the range of formulation options and increase patient compliance. Linguagen’s food and beverage program focuses on identifying flavor enhancers that improve the taste of existing ingredients, reduce the need for excess sugar and salt, and which contribute to the development of healthier, better-tasting foods and beverages.
Linguagen Corp.
CONTACT: Business, Scott M. Horvitz of Linguagen Corp., +1-609-860-1500,scott.horvitz@linguagen.com; or Media, Jennifer Garber of EnvironicsCommunications for Linguagen Corp., +1-203-325-8772, ext. 18,jgarber@environics-usa.com
Web site: http://www.linguagen.com/
